#United Kingdom #PACE #UTI #Bath #InnotiveDx

InnotiveDx Secures £1 Million Grant to Enhance UTI Diagnostics

Innotive Diagnostics, commonly known as InnotiveDx, is thrilled to announce a significant achievement in its journey towards combating antibiotic resistance. The company has successfully secured a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy). This funding is intended to advance the development of its innovative rapid diagnostic system specifically designed for urinary tract infections (UTIs) and the InnotiveUTI test.

The problem of urinary tract infections is a grave one globally, affecting hundreds of millions of individuals annually. It is estimated that UTIs account for more than 20% of all antibiotic prescriptions made worldwide. This high rate of antibiotic usage contributes significantly to the ongoing crisis of antibiotic resistance (AMR), which has become a severe challenge for health systems worldwide, leading to unnecessary hospital admissions and costing billions of dollars.

Recognizing the urgent need for effective solutions, InnotiveDx has developed a groundbreaking diagnostic technology that can deliver highly accurate results for bacterial identification and antimicrobial susceptibility testing (AST) in less than 60 minutes. Remarkably, the accuracy of the results in blinded evaluations exceeds 96%. Building on this promising technology, the grant from PACE will empower InnotiveDx to rigorously evaluate the precision and reliability of its systems against thousands of clinical samples prior to commencing a real-world clinical pilot study.

James Mainwaring, Chief Commercial and Operating Officer of InnotiveDx, expressed his enthusiasm regarding the grant, stating, "We are extremely pleased to have received this £1 million PACE grant; it is a tremendous endorsement of our technology, vision, and the hard work our team has put in since the inception of the company. Antibiotic resistance is one of humanity's most pressing challenges, and we are eager to tackle this issue in partnership with PACE and the broader corporate community."

Dr. Beverley Isherwood, the head of the PACE program, congratulated InnotiveDx on their successful application, noting, "We are delighted to welcome Innotive Diagnostics into the PACE portfolio after a highly competitive funding round for diagnostics. PACE will support InnotiveDx in further developing the InnotiveUTI with a collaborative approach, helping them generate the vital validation data needed to position their project for further development, funding, and investment."

InnotiveDx is a privately held in-vitro diagnostics company focused on creating a revolutionary diagnostic system that delivers rapid diagnoses of urinary tract infections, along with comprehensive bacterial identification and AST results within a mere 60 minutes at the point of care. Currently, such rapid diagnostic tools are not widely available, highlighting the innovative stride that InnotiveDx is making in the healthcare sector.

PACE (Pathways to Antimicrobial Clinical Efficacy) is recognized as one of the largest public-private initiatives in the UK, working collaboratively between Innovate UK, LifeArc, and Medicines Discovery Catapult to accelerate the discovery of early-stage antimicrobial drugs and diagnostics.

With the support of this grant, InnotiveDx is poised to make meaningful progress in addressing the pressing issue of antibiotic resistance and improving UTI management globally. As the fight against AMR intensifies, partnerships like the one forged with PACE are crucial for advancing innovative healthcare solutions.